Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Unraveling the Anticancer Effect of Curcumin and Resveratrol.

Pavan AR, Silva GD, Jornada DH, Chiba DE, Fernandes GF, Man Chin C, Dos Santos JL.

Nutrients. 2016 Nov 10;8(11). pii: E628. Review.

2.

Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast Cancer.

Shindikar A, Singh A, Nobre M, Kirolikar S.

J Oncol. 2016;2016:9750785. doi: 10.1155/2016/9750785. Review.

3.

DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics.

Bhattacharjee D, Shenoy S, Bairy KL.

Scientifica (Cairo). 2016;2016:6072357. doi: 10.1155/2016/6072357. Review.

4.

Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells.

Buhrmann C, Shayan P, Popper B, Goel A, Shakibaei M.

Nutrients. 2016 Mar 5;8(3):145. doi: 10.3390/nu8030145.

5.

Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells.

Kulbe H, Iorio F, Chakravarty P, Milagre CS, Moore R, Thompson RG, Everitt G, Canosa M, Montoya A, Drygin D, Braicu I, Sehouli J, Saez-Rodriguez J, Cutillas PR, Balkwill FR.

Oncotarget. 2016 Mar 29;7(13):15648-61. doi: 10.18632/oncotarget.7255.

6.

Qingyihuaji Formula Inhibits Pancreatic Cancer and Prolongs Survival by Downregulating Hes-1 and Hey-1.

Xu Y, Xu S, Cai Y, Liu L.

Evid Based Complement Alternat Med. 2015;2015:145016. doi: 10.1155/2015/145016.

7.

SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.

Chini CC, Espindola-Netto JM, Mondal G, Guerrico AM, Nin V, Escande C, Sola-Penna M, Zhang JS, Billadeau DD, Chini EN.

Clin Cancer Res. 2016 May 15;22(10):2496-507. doi: 10.1158/1078-0432.CCR-15-1760.

PMID:
26655844
8.
9.

Chemopreventive effect of resveratrol and apocynin on pancreatic carcinogenesis via modulation of nuclear phosphorylated GSK3β and ERK1/2.

Kato A, Naiki-Ito A, Nakazawa T, Hayashi K, Naitoh I, Miyabe K, Shimizu S, Kondo H, Nishi Y, Yoshida M, Umemura S, Hori Y, Mori T, Tsutsumi M, Kuno T, Suzuki S, Kato H, Ohara H, Joh T, Takahashi S.

Oncotarget. 2015 Dec 15;6(40):42963-75. doi: 10.18632/oncotarget.5981.

10.

Relationship of advanced glycation end products and their receptor to pelvic organ prolapse.

Chen Y, Huang J, Hu C, Hua K.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2288-99.

11.

In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment.

Fantini M, Benvenuto M, Masuelli L, Frajese GV, Tresoldi I, Modesti A, Bei R.

Int J Mol Sci. 2015 Apr 24;16(5):9236-82. doi: 10.3390/ijms16059236. Review.

12.

The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.

Li Y, Go VL, Sarkar FH.

Pancreas. 2015 Jan;44(1):1-10. doi: 10.1097/MPA.0000000000000257. Review.

13.

The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models.

Colin DJ, Limagne E, Ragot K, Lizard G, Ghiringhelli F, Solary É, Chauffert B, Latruffe N, Delmas D.

Cell Death Dis. 2014 Nov 20;5:e1533. doi: 10.1038/cddis.2014.486.

14.

Matrix metalloproteinases and gastrointestinal cancers: Impacts of dietary antioxidants.

Verma S, Kesh K, Ganguly N, Jana S, Swarnakar S.

World J Biol Chem. 2014 Aug 26;5(3):355-76. doi: 10.4331/wjbc.v5.i3.355. Review.

15.

Therapeutic options for the management of pancreatic cancer.

Rossi ML, Rehman AA, Gondi CS.

World J Gastroenterol. 2014 Aug 28;20(32):11142-59. doi: 10.3748/wjg.v20.i32.11142. Review.

16.

Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism.

Pal S, Bhattacharjee A, Ali A, Mandal NC, Mandal SC, Pal M.

J Inflamm (Lond). 2014 Aug 9;11:23. doi: 10.1186/1476-9255-11-23. Review.

17.

Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/β-catenin signaling pathway.

Fu Y, Chang H, Peng X, Bai Q, Yi L, Zhou Y, Zhu J, Mi M.

PLoS One. 2014 Jul 28;9(7):e102535. doi: 10.1371/journal.pone.0102535.

18.

Antichemosensitizing effect of resveratrol in cotreatment with oxaliplatin in HCT116 colon cancer cell.

Park DG.

Ann Surg Treat Res. 2014 Feb;86(2):68-75. doi: 10.4174/astr.2014.86.2.68.

19.

Natural compounds as anticancer agents: Experimental evidence.

Wang J, Jiang YF.

World J Exp Med. 2012 Jun 20;2(3):45-57. doi: 10.5493/wjem.v2.i3.45. Review.

20.

Resveratrol and cancer: focus on in vivo evidence.

Carter LG, D'Orazio JA, Pearson KJ.

Endocr Relat Cancer. 2014 May 6;21(3):R209-25. doi: 10.1530/ERC-13-0171. Review.

Supplemental Content

Support Center